GGrantIndex
← Leaderboards

S Gail Eckhardt

University Of Texas Hlth Sci Ctr San Ant

Google Scholar ↗PubMed ↗ORCID ↗
$7,082,740
Attributed
$8,527,467
Total exposure
16
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.7M · FY2005–20
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20

Funding mix

By agency

NIH$21,373,430 · 17

By mechanism

UM1$15,013,053 · 2
M01$2,244,805 · 9
T32$1,039,529 · 1
R21$1,024,849 · 1
K24$925,745 · 1
U01$763,990 · 1

Top collaborators

Most similar at University Of Texas Hlth Sci Ctr San Ant

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchClinical TrialsNeoplasm /Cancer ChemotherapyHuman SubjectDrug Screening /EvaluationClinical Trial Phase IHuman Therapy EvaluationPharmacokineticsTumorPathway InteractionsFacultyImageBaseInstitutionTrainingPublicationsOncologyMalignant NeoplasmsPatient PopulationColoradoPhase I Clinical TrialsLeadershipAntineoplasticsResearch Personnel

Grant awards (61)

Texas EXperimental Cancer Therapeutics Network - TEX CTN$5,697,447
UM1 · FY2020 · CA
Southwest Early Clinical Trials Consortium$1,029,321
UM1 · FY2019 · CA
Southwest Early Clinical Trials Consortium$320,000
UM1 · FY2019 · CA
Southwest Early Clinical Trials Consortium$120,746
UM1 · FY2019 · CA
Southwest Early Clinical Trials Consortium$2,167,090
UM1 · FY2018 · CA
Admin-Core-001$2,167,090
UM1 · FY2018 · CA
Southwest Early Clinical Trials Consortium$300,000
UM1 · FY2017 · CA
Southwest Early Clinical Trials Consortium$148,709
UM1 · FY2017 · CA
Southwest Early Clinical Trials Consortium$749,998
UM1 · FY2016 · CA
Southwest Early Clinical Trials Consortium$443,704
UM1 · FY2016 · CA
DEVELOPMENTAL THERAPEUTICS$36,909
P30 · FY2016 · CA · contact PI
Southwest Early Clinical Trials Consortium$918,950
UM1 · FY2015 · CA
DEVELOPMENTAL THERAPEUTICS$36,527
P30 · FY2015 · CA · contact PI
Southwest Early Clinical Trials Consortium$949,998
UM1 · FY2014 · CA
DEVELOPMENTAL THERAPEUTICS$33,433
P30 · FY2014 · CA · contact PI
DEVELOPMENTAL THERAPEUTICS$86,777
P30 · FY2013 · CA · contact PI
DEVELOPMENTAL THERAPEUTICS$963
P30 · FY2013 · CA · contact PI
DEVELOPMENTAL THERAPEUTICS$36,987
P30 · FY2012 · CA · contact PI
DEVELOPMENTAL THERAPEUTICS$28,496
P30 · FY2010 · CA · contact PI
Training in Pharmacology of Antineoplastic Agents$224,199
T32 · FY2009 · CA · contact PI
Development of Mechanism-Based Anticancer Therapy$193,015
K24 · FY2009 · CA · contact PI
DEVELOPMENTAL THERAPEUTICS$30,146
P30 · FY2009 · CA · contact PI
Training in Pharmacology of Antineoplastic Agents$217,921
T32 · FY2008 · CA · contact PI
Development of Mechanism-Based Anticancer Therapy$188,965
K24 · FY2008 · CA · contact PI
DEVELOPMENTAL THERAPEUTICS$28,350
P30 · FY2008 · CA · contact PI
Development of Mechanism-Based Anticancer Therapy$185,034
K24 · FY2007 · CA · contact PI
Phase I Trials of Anticancer Agents$177,121
U01 · FY2007 · CA · contact PI
Training in Pharmacology of Antineoplastic Agents$166,956
T32 · FY2007 · CA · contact PI
DEVELOPMENTAL THERAPEUTICS$27,575
P30 · FY2007 · CA · contact PI
Training in Pharmacology of Antineoplastic Agents$246,205
T32 · FY2006 · CA · contact PI
Development of Mechanism-Based Anticancer Therapy$181,218
K24 · FY2006 · CA · contact PI
Phase I Trials of Anticancer Agents$177,497
U01 · FY2006 · CA · contact PI
DEVELOPMENTAL THERAPEUTICS$15,296
P30 · FY2006 · CA · contact PI
Training in Pharmacology of Antineoplastic Agents$184,248
T32 · FY2005 · CA
Development of Mechanism-Based Anticancer Therapy$177,513
K24 · FY2005 · CA
Phase I Trials of Anticancer Agents$176,883
U01 · FY2005 · CA
Overcoming Age-Dependent Barriers to Early Phase Trials$591,498
R21 · FY2004 · CA
Phase I Trials of Anticancer Agents$117,489
U01 · FY2004 · CA
Overcoming Age-Dependent Barriers to Early Phase Trials$433,351
R21 · FY2003 · CA
Phase I Trials of Anticancer Agents$115,000
U01 · FY2003 · CA
PHASE I STUDY OF NSC 655649 GIVEN BY BOLUS INFUSION EVERY 21 DAYS$234,837
M01 · FY2002 · RR
SAFETY, TOLERANCE &PK STUDY OF RISING DOSE MSI 1256F (SQUALAMINE LACTATE)$234,837
M01 · FY2002 · RR
PHASE I STUDY OF NSC 655649 GIVEN BY BOLUS INFUSION EVERY 21 DAYS$234,837
M01 · FY2002 · RR
EVALUATION OF BAY 12 9566 IN COMBINATION W/ PACLITAXEL$234,837
M01 · FY2002 · RR
EVALUATION OF BAY 12 9566 IN COMBINATION W/ PACLITAXEL$234,837
M01 · FY2002 · RR
SAFETY, TOLERANCE &PK STUDY OF RISING DOSE MSI 1256F (SQUALAMINE LACTATE)$234,837
M01 · FY2002 · RR
COL 3 28 DAY ORAL DOSING CYCLE IN ADVANCED SOLID TUMORS$0
M01 · FY2002 · RR
COL 3 28 DAY ORAL DOSING CYCLE IN ADVANCED SOLID TUMORS$0
M01 · FY2002 · RR
SAFETY, TOLERANCE &PK STUDY OF RISING DOSE MSI 1256F (SQUALAMINE LACTATE)$234,837
M01 · FY2001 · RR
PHASE I STUDY OF NSC 655649 GIVEN BY BOLUS INFUSION EVERY 21 DAYS$234,837
M01 · FY2001 · RR
EVALUATION OF BAY 12 9566 IN COMBINATION W/ PACLITAXEL$234,837
M01 · FY2001 · RR
COL 3 28 DAY ORAL DOSING CYCLE IN ADVANCED SOLID TUMORS$0
M01 · FY2001 · RR
PHASE I EVALUATION OF IV MGI 114 GIVEN DAILY FOR 5 DAYS EVERY 28 DAYS$16,409
M01 · FY2000 · RR
PHASE I STUDY OF NSC 655649 GIVEN BY BOLUS INFUSION EVERY 21 DAYS$16,409
M01 · FY2000 · RR
EVALUATION OF BAY 12 9566 IN COMBINATION W/ PACLITAXEL$16,409
M01 · FY2000 · RR
PHASE I DOSE ESCALATION STUDY OF RECOMBINANT HUMAN CD40L LIGAND$16,409
M01 · FY2000 · RR
SAFETY, TOLERANCE &PK STUDY OF RISING DOSE MSI 1256F (SQUALAMINE LACTATE)$16,409
M01 · FY2000 · RR
PHASE I STUDY OF CGP 48664 IN CANCER PATIENTS$16,409
M01 · FY2000 · RR
PHASE I TRIAL OF BL 1001 AS 6 HOUR INFUSION$16,409
M01 · FY2000 · RR
PHASE I TRIAL OF PIVALOYLOXYMETHYLBUTYRATE (AN 9) AS A 6 HR INFUSION$16,409
M01 · FY2000 · RR
COL 3 28 DAY ORAL DOSING CYCLE IN ADVANCED SOLID TUMORS$0
M01 · FY2000 · RR